Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp

The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

NATCO launches additional strengths for generic version of Revlimid in USA

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions

LF is not a neglected disease but a priority disease for elimination: Dr. Mandaviya

Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023

The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.

Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US

All claims against the company in the litigation have now been dismissed.

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Lupin's subsidiary MedQuimica acquires rights to nine brands from Bausch Health

The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness

Delivery solution provider ZIM Laboratories Limited lists on NSE

The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.